Gumusay, Ozge
Huppert, Laura A.
Magbanua, Mark Jesus M.
Wabl, Chiara A.
Assefa, Michael
Chien, Amy Jo
Melisko, Michelle E.
Majure, Melanie C.
Moasser, Mark
Park, John
Rugo, Hope S. http://orcid.org/0000-0001-6710-4814
Funding for this research was provided by:
Eisai Incorporated
Article History
Received: 10 April 2023
Accepted: 6 August 2023
First Online: 10 October 2023
Declarations
:
: Amy Jo Chien: Research funding to institution: Merck, Puma, Amgen, Seagen. Michelle E. Melisko: Research funding to institution: Astra Zeneca, Novartis, KCRN Research, Puma, Seattle Genetics. For spouse: Speaker bureau/honoraria: AstraZeneca, Genentech, Gilead. Stock Ownership: Merrimack. John Park: Consulting/honoraria: AstraZenica, Genentech, Diichi, Gilead. Equity/stock ownership: Merrimack Pharma. Hope S. Rugo: Research support for clinical trials through the University of California: Pfizer, Merck, Novartis, Lilly, Roche, Daiichi, Seattle Genetics, Macrogenics, Sermonix, Boehringer Ingelheim, AstraZeneca, Astellas and Gilead. Honoraria from: Puma, Samsung, Mylan, Chugai, Blueprint, and NAPO. The remaining authors, declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.